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PURPOSE. The proteomic profile of vitreous from second-trimester human embryos and
young adults was characterized using mass spectrometry and analyzed for changes in
protein levels that may relate to structural changes occurring during this time. This vitreous
proteome was compared to previous reports to confirm proteins already identified and
reveal novel ones.
METHODS. Vitreous from 17 human embryos aged 14 to 20 weeks gestation (WG) and from a
12-, a 14-, a 15-, and a 28-year-old was individually analyzed using tandem mass
spectrometry–based proteomics. Peptide spectral count associations with embryonic age
were assessed using a general linear model of fold changes and Spearman’s rank correlation.
Differences between embryonic and young adult vitreous proteomes were also compared.
Immunohistochemistry was used to evaluate three proteins in five additional fetal (10–18
WG) human eyes.
RESULTS. There were 1217 proteins identified in fetal and young adult human vitreous, 206
after quantile normalization and variance filtering. In embryos, the peptide counts of 37
proteins changed significantly from 14 to 20 WG: 75.7% increased, 24.3% decreased.
Immunohistochemistry confirmed the absence of clusterin and cadherin in 10 and 14 WG
eyes and their presence at 18 WG. Comparing embryonic to young adult vitreous, 47 proteins
were significantly higher or lower. A total of 768 proteins not previously identified in the
literature are presented.
CONCLUSIONS. Proteins previously unreported in the human vitreous were identified. The
human vitreous proteome undergoes significant changes during embryogenesis and young
adulthood. A number of protein levels change considerably during the second trimester, with
the majority decreasing.
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Vitreous is an important ocular tissue that undergoesextensive developmental change ultimately resulting in an
optically clear tissue.1,2 During the first trimester (1–12 weeks
gestation [WG]) of ocular development, a complex vascular
network composed of the hyaloid artery, the vasa hyaloidia
propria, and the tunica vasculosa lentis develops within the
vitreous body to nourish the developing eye, particularly the
anterior segment and lens.1,3 During the second trimester
(approximately 13–26 WG) this hyaloid vasculature regresses,
and by birth the vitreous body is a mostly acellular, optically
clear gel.4–7
Proteomic analysis of vitreous has been previously used to
investigate hyaloid regression in postnatal mice.8,9 Proteomics
have also been used to characterize vitreous in a variety of
human diseases.10–24 The Human Eye Proteome Project is a
recent (2012) review and summary of the current status in
proteomic studies of the eye.25 This review identified 460
nonredundant human vitreous proteins in published literature.
A more recent study identified 1205 proteins in normal human
vitreous, 682 of which were previously unreported.26 To date,
proteomic studies of human embryonic vitreous have not been
undertaken. The rationale to do so is that protein expression
during this period of embryogenesis may be related to the
significant structural changes occurring during this stage of
vitreous development. The underlying hypothesis is that
vitreous protein composition changes from 14 to 20 WG and
differs at different fetal stages and in comparison to young
adulthood.
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METHODS
Study Design
This cross-sectional study analyzed the protein profiles of a
series of postmortem human embryonic vitreous samples aged
14 to 20 WG (N¼ 17) and a 12-, a 14-, a 15-, and a 28-year-old.
Five additional fetal eyes (10, 14, and 18 WG) were studied by
immunohistochemistry.
Vitreous Origin and Storage
Vitreous was obtained from 26 eyes [ages: 10 (n¼ 2), 14 (n¼
3), 15, 16, 17, 18, 18.5 (n¼ 3), 19 (n¼ 3), and 20 (n¼ 4) WG;
and 12, 14, 15, and 28 years old]. Human fetal eyes were
obtained at surgery to terminate pregnancy with maternal
consent and ethical approval from the Human Ethics Commit-
tees of the University of Sydney and the University of New
South Wales, in accordance with the tenets of the Declaration
of Helsinki. Ultrasound and postmortem measurements of foot
length were used to determine the gestational age. In all
subjects, the vitreous was obtained within 2 to 4 hours post
mortem. Only one vitreous body of each subject was employed
in this study. The fellow eye was employed for unrelated
studies of retinal embryology.
Eyes were examined at the time of dissection to confirm that
there was no gross pathology in the anterior and posterior
segments. Unfixed eyes were dissected with an initial incision
made approximately 1 to 2 mm posterior to the limbus
(depending on eye size), and then carefully extended around
the limbus using microscissors, so as to remove the anterior eye
structures (cornea, iris, and lens). The vitreous including hyaloid
vessels was removed with the lens, which was subsequently
removed during viewing with a dissecting microscope. For
human fetal eyes, the vitreous can be readily removed from the
eye cup as a ‘‘globule’’ or gel body. The entire vitreous was
immediately placed in sterile Eppendorf tubes, snap-frozen, and
stored at808C. No maternal or family history was available for
those subjects other than the age in WG. The young adult eyes
were obtained from the New England Eye Bank.
Vitreous Prefractionation and Proteomics
Fifty microliters of undiluted vitreous was separated by one-
dimensional SDS-PAGE, and proteins were visualized using
Coomassie Brilliant Blue G-250 stain (Bio-Rad, Hercules, CA,
USA). Each sample/gel lane was cut into 40 slices, and proteins
were subjected to in-gel digestion using trypsin (Promega,
Madison, WI, USA). Tryptic peptides were analyzed by nano-
spray liquid chromatography-tandem mass spectrometry (LC-
MS/MS) using a LTQ linear ion trap mass spectrometer
(Thermo Scientific, San Jose, CA, USA) as described previous-
ly.16,27 Proteins that were identified in at least two independent
vitreous samples by a minimum of two peptides matched in
the same or adjacent gel slices were reported. The total
peptide-spectral matches for each of these reported proteins
were compiled as a semiquantitative measure of protein
abundance. Proteins with peptide counts below this detection
threshold were considered zero concentrations.
Database Searching
All MS/MS samples were analyzed using X! Tandem (version X!
Tandem Piledriver [2015.04.01.1]; The GPM, thegpm.org, in
the public domain). X! Tandem was set up to search the
uni.HUMANRevConcat.2015_03.fasta.pro database (March
2015; 179,818 entries) assuming the digestion enzyme trypsin.
X! Tandem was searched with a fragment ion mass tolerance of
0.50 Da and a parent ion tolerance of 1.00 Da. Glu->pyro-Glu
of the n-terminus, ammonia loss of the n-terminus, gln->pyro-
Glu of the n-terminus, oxidation of methionine, and propiona-
mide of cysteine were specified in X! Tandem as variable
modifications.
Criteria for Protein Identification
Scaffold (version Scaffold_4.4.1.1; Proteome Software, Inc.,
Portland, OR, USA) was used to validate MS/MS-based peptide
and protein identifications. Peptide identifications were
accepted if they could be established at greater than 89.0%
probability to achieve a false discovery rate (FDR) less than
0.5% by the Scaffold Local FDR algorithm. Protein identifica-
tions were accepted if they could be established at greater than
99.0% probability to achieve an FDR less than 1.0% and
contained at least two identified peptides. Protein probabilities
were assigned by the Protein Prophet algorithm.28 Proteins
that contained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony. Proteins were annotated with GO
terms from the National Center for Biotechnology Information
(downloaded April 24, 2015).29
Statistical Analyses
Spectral peptide counts were normalized using quantile normal-
ization. A variance filtering procedure was applied such that
proteins with zero values for >50% of their data within an age
group were excluded from analysis. Age groups [early embryonic
(14–18 WG,N¼7), late embryonic (19–20 WG,N¼7), and young
adult (12, 14, 15 and 28 years old,N¼4)] were compared using a
general linear model of the log values from the normalized data.
Fold changes are presented. P values were adjusted for FDR using
the Benjamini-Hochberg (BH) correction.30 Spearman rank-order
correlations were additionally conducted between the embry-
onic age and proteins. Analyses were conducted in Stata Version
13.1 (StataCorp LP; College Station, TX, USA).
Immunohistochemistry (IHC)
Dystroglycan and cadherin were found to undergo statistically
significant change in peptide numbers from 14 to 20 WG, and
clusterin similarly changed from the embryo to young
adulthood. The commercial availability of human antibodies
to these proteins enabled IHC evaluation in embryonic human
eyes as previously described by our group.31–33
Five formalin-fixed, paraffin-embedded whole human eyes
from embryos aged 10 (n ¼ 2), 14 (n ¼ 2), and 18 WG were
used for histologic examination of the hyaloid vasculature.
Immunohistochemistry experiments were performed in dupli-
cate in the same eye and, when tissue was available, in multiple
eyes of the same gestational age. Whole eye cups were
processed and embedded in paraffin and serially sectioned at
the horizontal meridian from cornea to optic nerve at 5 lm.
Commercially available primary antibodies (Novus Biologicals,
LLC, Littleton, CO, USA) directed against dystroglycan,
cadherin, and clusterin were employed. Deparaffinization and
rehydration were performed using a series of baths beginning
with xylene, 100%, 95%, and 70% ethanol, with a final wash in
distilled water. Antigen retrieval was performed using a sodium
citrate buffer solution at pH 6.0 (Dako, Carpinteria, CA, USA)
and heating under pressure in a microwave oven. The slides
were rinsed and washed in a buffer (0.05 M Tris/HCl, 0.15 M
NaCl, 0.05% Tween 20, pH 7.6) between each step of the IHC
protocol. Three percent hydrogen peroxide was used for 10
minutes to block endogenous peroxidase. Rabbit anti-human
primary polyclonal antibody for each protein was diluted to the
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manufacturer’s recommendation using an antibody diluent
with background reducer (Dako) and incubated on the
sections for 1 hour. Horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (Dako) was applied to the
sections and allowed to incubate for one-half hour. The brown-
colored enzyme product was developed using a 3,30-diamino-
benzidine (DAB) chromogen (Dako) for 5 minutes. The
sections were counterstained using Mayer’s hematoxylin
(Dako) for 30 seconds, washed in distilled water, then
dehydrated in ascending graded ethanol baths, cleared in
xylene, and coverslipped using a permanent mounting media.
The immunostained slides were examined on a Zeiss Axioskop
bright-field microscope (Carl Zeiss, Inc., Thornwood, NY,
USA). The images were acquired using a Spot II digital camera
(Diagnostics Instruments, Inc., Sterling Heights, MI, USA).
RESULTS
Mass spectrometry identified 1217 proteins (Supplementary
Table S1) in at least two independent vitreous samples when all
subjects (from 14 WG to 28 years of age) were considered.
After quantile normalization and variance filtering, 206
proteins remained.
Human Fetal Vitreous Compared to Young Adult
Samples were divided into dichotomous age groups, embry-
onic (14–20 WG) and young adult (12, 14, 15, and 28 years
old), and the proteomes were compared. Forty-seven proteins
(23%) were differentially expressed between the embryonic
and young adult vitreous. All of these identified proteins had
peptide count values that were significantly lower in the
embryonic vitreous, with the fold change ranging from 1.5 to
11 times lower in the embryonic vitreous; the average fold
change was 3 times lower (Table 1).
Fetal Vitreous Changes From 14 to 20 WG
Early (14–18 WG) and late (19–20 WG) second-trimester age
groups were also compared using a general linear model of the
TABLE 1. Comparison of Embryonic Versus Young Adult Vitreous
Proteins With FDR Adjusted P Values < 0.05
UniProtKB ID %D P FDR
ALDOA_HUMAN 72 <0.001
H3BR04_HUMAN 64 <0.001
PTGDS_HUMAN 82 <0.001
A1AG1_HUMAN 76 <0.001
K7EKH5_HUMAN 83 <0.001
KAD1_HUMAN 72 <0.001
PARK7_HUMAN 59 <0.001
MDHC_HUMAN 67 <0.001
PRDX6_HUMAN 67 <0.001
TBAL3_HUMAN 71 <0.001
H0Y7L5_HUMAN 86 <0.001
APOE_HUMAN 84 <0.001
A0A075B6N8_HUMAN 82 <0.001
A0A0A0MS08_HUMAN 72 <0.001
A0A0A0MSI0_HUMAN 50 <0.001
A0A087WYC5_HUMAN 73 <0.001
PGK1_HUMAN 75 <0.001
DDAH1_HUMAN 79 <0.001
UCHL1_HUMAN 55 0.001
GPX3_HUMAN 90 0.001
KPYM_HUMAN 91 0.001
A1AG2_HUMAN 68 0.001
CLUS_HUMAN 80 0.001
PEDF_HUMAN 87 0.001
IPYR_HUMAN 62 0.001
A0A087WV47_HUMAN 72 0.001
CBR1_HUMAN 85 0.002
IGHG2_HUMAN 84 0.002
OSTP_HUMAN 64 0.002
DKK3_HUMAN 70 0.002
TALDO_HUMAN 54 0.002
A0A087X010_HUMAN 65 0.003
A0A087X1C7_HUMAN 66 0.003
LDHB_HUMAN 39 0.005
CO4A_HUMAN 67 0.007
J3QQX2_HUMAN 54 0.008
X6RA14_HUMAN 68 0.009
PGAM1_HUMAN 57 0.010
PEA15_HUMAN 57 0.016
OPT_HUMAN 84 0.017
B4GA1_HUMAN 78 0.019
G3V461_HUMAN 77 0.022
H7BYH4_HUMAN 56 0.029
TRFE_HUMAN 49 0.031
TBA1B_HUMAN 43 0.043
TBA1A_HUMAN 43 0.043
F8VZY9_HUMAN 81 0.045
Proteins are listed using Universal Protein Resource ID. The UniProt
Knowledgebase (UniProtKB) is the central hub for the collection of
functional information on proteins, with accurate, consistent, and rich
annotation (http://www.uniprot.org/help/uniprotkb, in the public
domain).
TABLE 2. Vitreous Proteins That Increased When Comparing Early
(14–18 WG) Versus Late (19–20 WG) Second-Trimester Proteins [FDR
Adjusted P Values < 0.05]
UniProtKB ID
14–18 WG vs. 19–20 WG
%D P FDR
G3XAM2_HUMAN þ173 <0.001
DAG1_HUMAN þ196 0.003
LV106_HUMAN þ249 0.003
PCSK1_HUMAN þ128 0.003
A0A087WZW8_HUMAN þ146 0.003
A0A087WYL9_HUMAN þ81 0.004
A0A087X130_HUMAN þ80 0.008
PTGDS_HUMAN þ435 0.008
ZA2G_HUMAN þ228 0.008
C9JEV0_HUMAN þ223 0.010
A0A087WV47_HUMAN þ147 0.012
APOE_HUMAN þ127 0.012
NRCAM_HUMAN þ142 0.016
FAM3C_HUMAN þ212 0.016
A0A075B6K9_HUMAN þ128 0.019
OSTP_HUMAN þ353 0.019
A0A0A0MS08_HUMAN þ119 0.019
ANT3_HUMAN þ199 0.019
A0A087X1C7_HUMAN þ157 0.028
VTDB_HUMAN þ135 0.028
H0Y7L5_HUMAN þ133 0.030
A0A087X010_HUMAN þ120 0.031
PEDF_HUMAN þ100 0.035
PRS35_HUMAN þ409 0.036
A0A075B6N8_HUMAN þ262 0.044
KV302_HUMAN þ170 0.044
CYTC_HUMAN þ238 0.045
A0A087WXC3_HUMAN þ108 0.045
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log values from the normalized data; 37/206 (18.0%) proteins
were statistically different between early versus late age groups
using a BH-corrected P value (P < 0.05) and had a fold change
that ranged from 0.27 to 5.35. Table 2 lists those proteins that
increased and Table 3 lists those that decreased when
comparing early (14–18 WG) to late (19–20 WG) second
trimester.
Spearman’s rank correlation of the total peptide counts (all
proteins) showed that there was no statistically significant (R¼
0.37, P < 0.15) increase or decrease in overall proteins from 14
to 20 WG. Analysis of changes in individual proteins showed
that there was a significant increase or decrease in quantile-
normalized peptide spectral counts from 14 to 20 WG (BH FDR
P < 0.05) in 30.1% (62/206) of proteins (Table 4). Of note,
each protein found to decrease from 14 to 20 WG by
Spearman’s rank correlation analysis was also found to be
TABLE 3. Vitreous Proteins That Decreased When Comparing Early
(14–18 WG) Versus Late (19–20 WG) Second-Trimester Proteins [FDR
Adjusted P Values < 0.05]
UniProtKB ID
14–18 WG vs. 19–20 WG
%D P FDR
HNRPD_HUMAN 52 0.008
PRDX5_HUMAN 69 0.010
COF1_HUMAN 59 0.011
A8MX94_HUMAN 54 0.018
TAGL2_HUMAN 59 0.019
CAPZB_HUMAN 52 0.026
ROA2_HUMAN 70 0.031
ENOA_HUMAN 73 0.044
CAZA1_HUMAN 56 0.045
TABLE 4. Spearman’s Correlation of Vitreous Protein Counts With Embryonic Ages (14–20 WG, n ¼ 17)
Positive Correlations, Increased Expression Negative Correlations, Decreased Expression
UniProtKB ID q P FDR UniProtKB ID q P FDR
PTGDS_HUMAN 0.873 0.001 PRDX5_HUMAN 0.799 0.005
PRS35_HUMAN 0.815 0.005 6PGD_HUMAN 0.731 0.009
LUM_HUMAN 0.807 0.005 A8MX94_HUMAN 0.729 0.009
OSTP_HUMAN 0.806 0.005 ROA2_HUMAN 0.704 0.012
B4GA1_HUMAN 0.796 0.005 TAGL2_HUMAN 0.689 0.013
DKK3_HUMAN 0.785 0.006 ENOA_HUMAN 0.688 0.013
FHR1_HUMAN 0.780 0.006 LDHB_HUMAN 0.679 0.014
A1AG2_HUMAN 0.777 0.006 1433E_HUMAN 0.669 0.016
A0A0B4J1Z6_HUMAN 0.770 0.006 ACTG_HUMAN 0.666 0.017
RARR2_HUMAN 0.766 0.006 HNRPD_HUMAN 0.666 0.017
A0A075B6K9_HUMAN 0.760 0.006 COF1_HUMAN 0.638 0.026
KV302_HUMAN 0.755 0.006 CAPZB_HUMAN 0.625 0.030
A0A087WYL9_HUMAN 0.753 0.006 ALDR_HUMAN 0.614 0.034
DAG1_HUMAN 0.753 0.006 H0YJG0_HUMAN 0.613 0.034
LV106_HUMAN 0.753 0.006 1433T_HUMAN 0.603 0.039
CADH2_HUMAN 0.745 0.007 CAZA1_HUMAN 0.596 0.041
A0A075B6N8_HUMAN 0.739 0.008 IF4A2_HUMAN 0.579 0.049
B2MG_HUMAN 0.728 0.009
A0A087X130_HUMAN 0.725 0.009
PCSK1_HUMAN 0.724 0.009
NRCAM_HUMAN 0.722 0.009
KV102_HUMAN 0.713 0.011
G3XAM2_HUMAN 0.706 0.012
ZA2G_HUMAN 0.704 0.012
A0A087WXC3_HUMAN 0.701 0.012
FAM3C_HUMAN 0.699 0.012
SCG1_HUMAN 0.694 0.013
A1AG1_HUMAN 0.693 0.013
C9JEV0_HUMAN 0.692 0.013
KV104_HUMAN 0.691 0.013
A0A087WZW8_HUMAN 0.686 0.013
CYTC_HUMAN 0.683 0.014
PEDF_HUMAN 0.677 0.015
A0A087X1C7_HUMAN 0.672 0.016
A0A0A0MS08_HUMAN 0.661 0.018
A0A087WV47_HUMAN 0.657 0.019
C9JC84_HUMAN 0.635 0.027
K1C14_HUMAN 0.629 0.029
F8VZY9_HUMAN 0.622 0.031
IGHG2_HUMAN 0.617 0.033
A0A087X010_HUMAN 0.611 0.034
VTDB_HUMAN 0.599 0.040
PGBM_HUMAN 0.594 0.042
ANT3_HUMAN 0.582 0.049
CO4A_HUMAN 0.581 0.049
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decreased by the grouped (14–18 vs. 19–20 WG) analysis
described above. The same was true for each protein that
increased during 14 to 20 WG, confirming these results.
Of these 62, 45 (72.6%) proteins had increased expression
during this period of gestation (R > 0.58, BH FDR P < 0.05).
Notable in this group is cadherin (cadh2) (R ¼ 0.745, P 
0.008), which is important for cell adhesion.34 Pigment
epithelium-derived factor (PEDF), which has been shown to
be important in antiangiogenesis,14,35–38 was also found to
increase significantly with fetal age from 14 to 20 WG (R ¼
0.677, P < 0.015). Cytochrome C (cytc), a known mediator of
developmental apoptosis,39 had increased expression (R ¼
0.683, P < 0.014), as did dystroglycan (dag1), the laminin
binding component of the dystrophin-glycoprotein complex40
(R ¼ 0.753, P < 0.007).
Of the 62 proteins with levels that changed significantly
from 14 to 20 WG, 17 (27.4%) had decreased expression (R <
0.580, BH FDR P < 0.05). Notable proteins that decreased
were cofilin-1 (cof1; R ¼0.638, BH FDR P < 0.026), which
has been shown to promote/mediate angiogenesis,41 peroxir-
edoxin (prdx5; R ¼0.799, P < 0.005), which may play an
antioxidant protective role,42 and glycolytic enzyme enolase43
(enoa; R¼0.688, P < 0.013).
Immunohistochemistry
Immunohistochemistry studies confirmed the presence of
dystroglycan, clusterin, and cadherin, all shown to have a
significant difference in expression in human embryonic
vitreous. Positive staining was localized in hyalocytes and
hyaloid vessels. Clusterin and cadherin were not detected in 14
WG vitreous cells or structures (Figs. 1A, 2A) but did appear in
the hyaloid vasculature by 18 WG (Figs. 1B, 2B). This is
consistent with the increase in protein concentrations
detected in the proteomic analyses (see above). Dystroglycan
was detected in the hyaloid vessels of all five embryonic eyes
(10, 14, 18 WG; Fig. 3). Immunohistochemical detection of
these proteins in hyalocytes and in hyaloid vessels of human
embryos suggests that at least these particular proteins that
were detected by proteomics originated from vitreous or
structures within the vitreous body. This same approach of
confirming proteomics with IHC has been previously been
employed by others to study hyaloid vessel regression in the
mouse.8
DISCUSSION
Proteomic investigation of vitreous composition in 14 to 20
WG human embryos and young adult human eyes revealed a
complex tissue with 1217 detectable proteins, of which 206
were quantile normalized and variance filtered. While many of
these are likely native to vitreous, especially in the embryo,
many may also arise from adjacent tissues such as the vascular
and neuronal elements of the retina and ciliary body. A review
of previously reported human vitreous proteins identified 545
nonredundant proteins.25 A recent high-resolution Fourier
transform study of the normal human vitreous proteome
FIGURE 1. Immunohistochemistry in a 14 WG human vitreous
demonstrates that clusterin was not detected in the hyaloid vessels
(A) and cadherin was not detected in the endothelial cells of the
hyaloid vessels (B). Scale bar: 10 lm.
FIGURE 2. Immunohistochemistry in an 18 WG human vitreous
demonstrates that positive staining for clusterin in the hyaloid vessels
(A) and cadherin was detected in the endothelial cells of the hyaloid
artery (B). This immunostaining pattern confirmed the results of
proteomics analysis, which showed that clusterin and cadherin
increased from 14 to 20 WG. Scale bar: 10 lm.
Proteomics of Embryonic and Young Human Vitreous IOVS j November 2015 j Vol. 56 j No. 12 j 7040
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934655/ on 08/07/2016
identified 1205 proteins, 682 (57%) of which had not been
previously described in vitreous.26 The study reported herein
identified 1217 vitreous proteins, 744 (61%) of which had not
been previously reported in either of the aforementioned
studies (Fig. 4).
The protein composition of human embryonic vitreous
differs from young adult vitreous and changes significantly
from 14 to 20 WG, during the second trimester of gestation.
This occurs concurrently with regression of embryonic
vitreous vessels as well as other developmental changes in
the eye. Of the 206 quantile-normalized/variance-filtered
proteins identified in human fetal vitreous, 37 (18%) showed
a significant change in expression from 14 to 20 WG (early to
late second trimester). Some of these, such as PEDF and cofilin-
1, are known to be important in angiogenesis and may be
critically involved in this and one or more other processes of
vitreous or ocular embryogenesis. Thus, it is intriguing to
postulate that some of the changes detected in the proteomic
profile of human fetal vitreous during the second trimester are
related to the regression of the embryonic vitreous vasculature,
although other developmental events are also occurring during
this period. In this context, a better understanding of hyaloid
vasculature regression may prove useful in developing new
therapies for vasoproliferative eye diseases, metastatic carci-
nomas, and others. To this end, the proteins identified in this
study, especially those shown to change in concentration and
those corroborated in previous studies, may be worth
exploring as potential avenues for new therapeutic approaches
to both stimulate endogenous inhibitory pathways and
suppress stimulatory pathways in the management of neovas-
cular pathologies.
A similar proteomic study was undertaken in the develop-
ing mouse vitreous using two-dimensional gel electrophoresis
(2DE), a distinctly different methodology than that employed
in the present study.8 Furthermore, the mouse specimens
consisted of lens with pupillary membrane, tunica vasculosa
lentis, and vasa hyaloidea propria, while the specimens in the
present study were purely vitreous. This may explain why only
a small number of proteins were found in both mouse and
human proteomes. This and contradictory findings regarding
changes from early to late fetal stages are possibly due to
different methodologies as well as species differences.
Future studies should explore the fetal human proteome in
search of ‘‘missing proteins’’44 with the findings validated by
multiple reaction monitoring (MRM) methodologies, as has
been previously described.45
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